

Long-Acting Reversible Contraceptives: Intrauterine Devices and the Contraceptive Implant

Eve Espey, MD, MPH, and Tony Ogburn, MD

Obstet Gynecol 2011;117(3)

ACCME Accreditation

The American College of Obstetricians and Gynecologists (ACOG) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. (*Continuing medical education credit for "Long-Acting Reversible Contraceptives: Intrauterine Devices and the Contraceptive Implant" will be available through March 2014.*)

AMA PRA Category 1 Credit™ and ACOG Cognate Credit

The American College of Obstetricians and Gynecologists (ACOG) designates this educational activity for a maximum of 2 AMA PRA Category 1 Credits™ or up to a maximum of 2 Category 1 ACOG Cognate credits. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Disclosure Statement

Current guidelines state that continuing medical education (CME) providers must ensure that CME activities are free from the control of any commercial interest. All authors, reviewers, and contributors have disclosed to ACOG all relevant financial relationships with any commercial interests. The authors, reviewers, and contributors declare that neither they nor any business associate nor any member of their immediate families has a financial interest or other relationships with any manufacturer of products or any providers of services discussed in this program. Any conflicts have been resolved through group and outside review of all content.

Before submitting this form, please print a completed copy as confirmation of your program participation.

ACOG Fellows: To obtain credits, complete and return this form by clicking on "Submit" at the bottom of the page. Credit will be automatically recorded upon receipt and online transcripts will be updated twice monthly. ACOG Fellows may check their transcripts online at <http://www.acog.org>.

Non-ACOG Fellows: To obtain credits, submit the printout of the completed quiz to your accrediting institution. The printout of the completed quiz is documentation for your continuing medical education credits.

1. The most common reason for a reversible contraceptive method to fail is:

- A. Inconsistent use
- B. Biologic variability
- C. Inconsistent ovulation cycles
- D. Extended sperm survival
- E. Drug–drug interaction

2. According to the U.S. Medical Eligibility Criteria (MEC) for Contraceptive Use, 2010, use of a contraceptive method in the face of a condition for which the theoretical or proven risks usually outweigh the advantages of using the method would be classified as a:
- A. 1
 - B. 2
 - C. 3
 - D. 4
3. The greatest risk for infection in women using intrauterine devices (IUDs) occurs:
- A. In nulliparous women
 - B. In the first 20 days of use
 - C. Near the end of the effective life of the device
 - D. In immediate postpartum insertions
 - E. In women who are smokers
4. The U.S. MEC gives IUD use in nulliparous women a rating of:
- A. 1
 - B. 2
 - C. 3
 - D. 4
5. When compared to interval insertion, insertion of an IUD at the time of miscarriage is associated with complication rates that are:
- A. Significantly higher
 - B. Slightly higher
 - C. Unchanged
 - D. Slightly lower
 - E. Significantly lower

6. The levonorgestrel intrauterine system (LNG IUS) is approved by the Food and Drug Administration (FDA) for the indications of contraception and:
- A. Adenomyosis
 - B. Pelvic pain
 - C. Endometrial hyperplasia
 - D. Heavy bleeding
 - E. Uterine leiomyomas
7. A 17-year-old woman requests placement of an IUD. Samples are taken for sexually transmitted diseases (STDs) and the IUD is placed. The subsequent results of this screening are reported to be positive. The most appropriate next step in the management of this patient is:
- A. Administer antibiotic treatment for the STD as per standard protocol
 - B. Remove the IUD and administer antibiotic treatment for the STD as per standard protocol
 - C. Administer antibiotic treatment for the STD but at double the normal dosage rate
 - D. Remove and culture the IUD directly, defer treatment until the results are known
 - E. Retest for the STD in 7 to 10 days following the insertion
8. Prior to adding the progesterone implant to one's practice, the FDA has mandated that the practitioner complete:
- A. A registration process with the federal government
 - B. An online questionnaire
 - C. A federal background check
 - D. A 3-hour training and simulation course
 - E. A TSA pat-down
9. The most common reason for pregnancy in women using the progesterone contraceptive implant is:
- A. Inadequate absorption of progesterone from the device
 - B. Increased metabolic clearance of progesterone in some patients
 - C. Obesity
 - D. Scar formation around the device
 - E. Non-insertion of the device

10. When compared to a woman's natural bleeding pattern, users of the progesterone contraceptive implant are likely to have:

- A. Amenorrhea
- B. Infrequent bleeding
- C. Unchanged number of days but unpredictable pattern
- D. Increased number of days bleeding
- E. Fewer days of bleeding but with increased flow

ACOG ID Number:

Name:

Address:

City/State/Zip:

Actual time spent completing this activity (you may record up to 2 hours):

EXPIRED